Clinical Trials
36 trialsNCT04632459 2026-06-05
Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer
Samsung Medical Center
Phase 2 Completed
NCT05379972 2026-06-05
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
University of Colorado, Denver
Phase 2 Completed
NCT04379596 2026-05-13
DG-03
AstraZeneca
Phase 2 Recruiting
NCT03797326 2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04745988 2026-04-09
An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric Cancer
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT03505320 2026-04-03
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT06109467 2026-02-09
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07176312 2026-02-04
ZANGEA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT03257163 2026-01-20
Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT04798781 2025-12-11
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Cedars-Sinai Medical Center
Phase 2 Completed
NCT04209686 2025-12-03
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04768686 2025-09-25
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Hanmi Pharmaceutical Company Limited
Phase 2 Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT05311176 2025-05-11
nextHERIZON
Imugene Limited
Phase 2 Terminated
NCT03609359 2025-04-16
Lenva+Pembro
National Cancer Center Hospital East
Phase 2 Completed
NCT03064490 2025-04-10
PROCEED
Duke University
Phase 2 Completed
NCT04508140 2024-11-29
Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Highlight Therapeutics
Phase 2 Terminated
NCT03382600 2024-06-11
KEYNOTE-659
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03321630 2024-03-27
A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
NYU Langone Health
Phase 2 Completed
NCT04249739 2024-03-13
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
Samsung Medical Center
Phase 2 Unknown
NCT06036745 2024-03-07
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
Shanghai Minimally Invasive Surgery Center
Phase 2 Recruiting
NCT02918162 2024-02-15
Perioperative Chemo and Pembrolizumab in Gastric Cancer
Columbia University
Phase 2 Completed
NCT03196232 2024-01-23
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Stanford University
Phase 2 Completed
NCT04519151 2023-06-08
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center
Phase 2 Recruiting
NCT03488667 2023-05-19
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT02954536 2023-03-16
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04099641 2023-02-08
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
OncXerna Theraputics, Inc.
Phase 2 Completed
NCT04510285 2023-02-01
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02335411 2022-08-08
KEYNOTE-059
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03122548 2019-04-04
Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers
Aduro Biotech, Inc.
Phase 2 Terminated
NCT02943603 2018-07-13
A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
University of Pittsburgh
Phase 2 Withdrawn